insitro and Bristol Myers Squibb Collaboration Expanded with Nomination of New Targets
Monday, March 23, 2026 1 min read
Key Takeaway: Insitro has expanded its collaboration with Bristol Myers Squibb to enhance its portfolio of therapeutic programs targeting amyotrophic lateral sclerosis (ALS). The partnership aims to accelerate the development of disease-modifying interventions that address the biological drivers of ALS. Bristol Myers Squibb has nominated two additional targets as part of this initiative.
Market Sentiment Analysis
POSITIVE FACTORS
Expansion of collaboration with Bristol Myers Squibb.
Focus on advancing therapeutic programs for ALS.
Aim to deliver disease-modifying interventions.
Full Press Release Details
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced the expansion of its strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to advance a broadened portfolio of therapeutic programs for amyotrophic lateral sclerosis (ALS). The collaboration is focused on accelerating and delivering disease-modifying interventions designed to address the underlying biological drivers of ALS. BMS has nominated two additional targets
Frequently Asked Questions
What is the focus of the Insitro and BMY collaboration?
The collaboration focuses on advancing therapeutic programs for amyotrophic lateral sclerosis (ALS).
What new developments are included in the collaboration?
Bristol Myers Squibb has nominated two additional targets as part of the expanded collaboration.
What is the goal of the therapeutic programs?
The goal is to accelerate and deliver disease-modifying interventions for ALS.
Where is Insitro based?
Insitro is based in South San Francisco, California.